AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
2.230
-0.080 (-3.46%)
Mar 31, 2025, 1:17 PM EDT - Market open
AbCellera Biologics Revenue
In the year 2024, AbCellera Biologics had annual revenue of $28.83M, down -24.17%. AbCellera Biologics had revenue of $5.05M in the quarter ending December 31, 2024, a decrease of -44.98%.
Revenue (ttm)
$28.83M
Revenue Growth
-24.17%
P/S Ratio
23.58
Revenue / Employee
$48,378
Employees
596
Market Cap
664.51M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ABCL News
- 5 days ago - AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 - Business Wire
- 4 weeks ago - AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - AbCellera Reports Full Year 2024 Business Results - Business Wire
- 6 weeks ago - AbCellera to Participate at Upcoming Investor Conferences in March - Business Wire
- 2 months ago - AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 - Business Wire
- 2 months ago - AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology - Business Wire
- 3 months ago - AbCellera Biologics: Still A Concept Stock - Seeking Alpha
- 4 months ago - AbCellera to Present at Upcoming Investor Conferences in December and January - Business Wire